Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Azelaprag,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
BioAge Doses First Patient in Phase 2 Trial of Azelaprag for Obesity with Tirzepatide
Details : BGE-105 (azelaprag), an oral apelin receptor agonist in combination with Lilly’s Zepbound (tirzepatide) and other incretins for the treatment of obesity.
Brand Name : BGE-105
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 29, 2024
Lead Product(s) : Azelaprag,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Azelaprag,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Sofinnova Investments
Deal Size : $170.0 million
Deal Type : Series D Financing
Details : The funding will be used to support Phase II clinical development of BioAge’s lead compound BGE-105 (azelaprag), an oral apelin receptor agonist in combination with Lilly’s Zepbound (tirzepatide) and other incretins for the treatment of obesity.
Brand Name : BGE-105
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 13, 2024
Lead Product(s) : Azelaprag,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Sofinnova Investments
Deal Size : $170.0 million
Deal Type : Series D Financing
Lead Product(s) : Azelaprag,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Collaboration
Details : As part of the collaboration, Lilly will supply tirzepatide and Chorus will provide clinical trial design and execution expertise. BioAge retains worldwide exclusive rights to develop and commercialize BGE-105 (azelaprag) for all indications.
Brand Name : BGE-105
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 26, 2023
Lead Product(s) : Azelaprag,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?